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Bacteria that cause disease rely on their ability to
counteract and overcome host defenses. Here, we
present a genome-scale study of Mycobacterium
tuberculosis (Mtb) that uncovers the bacterial deter-
minants of surviving host immunity, sets of genes we
term ‘‘counteractomes.’’ Through this analysis, we
found that CD4 T cells attempt to containMtb growth
by starving it of tryptophan—a mechanism that
successfully limits infections by Chlamydia and
Leishmania, natural tryptophan auxotrophs. Mtb,
however, can synthesize tryptophan under stress
conditions, and thus, starvation fails as anMtb-killing
mechanism. We then identify a small-molecule inhib-
itor of Mtb tryptophan synthesis, which converts Mtb
into a tryptophan auxotroph and restores the efficacy
of a failed host defense. Together, our findings
demonstrate that the Mtb immune counteractomes
serve as probes of host immunity, uncovering
immune-mediated stresses that can be leveraged
for therapeutic discovery.
INTRODUCTION
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuber-
culosis (TB), remains one of the world’s major bacterial patho-
gens. After a century-long decline, the last few decades have
seen a resurgence in TB, with an estimated 2 billion people
infected and about 1.7 million deaths per year (WHO, 2011).
The success of Mtb as a pathogen lies in its adaptation to the
human host and its capacity to counteract themany arms of anti-
bacterial immunity (Ernst, 2012). Its ability to survive host
defenses is directly responsible for the large reservoir of infected
people, whereas its ability to subvert bactericidal mechanisms1296 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.allows it to replicate in vivo and cause disease (Ehrt and Schnap-
pinger, 2009). Elucidating these mechanisms will help us to
understand the complex host-pathogen interface, and targeting
these mechanisms is an underutilized therapeutic strategy that
can help patients’ immune systems kill Mtb.
In the multifaceted immune response against Mtb, CD4 T cells
make up one of the most biologically and epidemiologically
important compartments. Humans and mice generally cannot
clear Mtb during infection, but both are able to limit bacterial
growth, and in the case of immunocompetent humans, prevent
disease (Ernst, 2012; Flynn, 2006). This response is dependent
on CD4 T cells. The CD4-deficient MHC class II knockout (KO)
mice, and other mice that lack CD4 T cells, cannot stop myco-
bacterial growth and rapidly succumb to disease and death
(Cosgrove et al., 1991; Grusby et al., 1991; Mogues et al.,
2001; Scanga et al., 2000). In human disease, progressive CD4
T cell loss due to HIV infection also increases the risk for TB
disease and death (Pawlowski et al., 2012; Selwyn et al., 1989).
However, crucial as they are for TB immunity, CD4 T cells ulti-
mately fail to sterilize infection. The surviving bacteria remain
latent, with the potential to cause disease in the future (Ernst,
2012; Flynn, 2006). The nature of the environment imposed by
CD4 T cells, enough to limit growth but not kill Mtb, is not well
studied. Reports have shown that the Th1 subset is especially
effective in limiting Mtb growth, and cytokines such as IFN-g
and TNF-a are needed in some, but not all, models of CD4
T cell-mediated defenses (Bold et al., 2011; Flynn et al., 1993,
1995; Gallegos et al., 2011; Nandi and Behar, 2011; Scanga
et al., 2000). But the exact nature of CD4-mediated stress—the
repertoire of antipathogen effectors induced by CD4 T cells—is
poorly understood. Knowing how CD4 T cells attempt to kill
Mtb and how Mtb survives could identify Mtb vulnerabilities
and aid drug discovery efforts.
Here, we profile the mycobacterial genetic requirements for
surviving the CD4 response, the CD4 ‘‘counteractome.’’ We
compare this with relevant in vitro survival signatures such
as acid, oxidative stress, and nutrient starvation, creating
Figure 1. Mtb Genes Required for Infection
of WT and MHCII/ Mice
(A) MHC class II KO and WT mice were infected
with 106 bacilli from our transposon library. At 10
and 45 days after infection, four mice in each
group were sacrificed, and spleen homogenates
were plated to recover surviving bacteria. To
discover genes required for surviving CD4 T cell
immunity, we searched for genes that were
required for growth in aWTmouse but not required
in the MHC class II mice.
(B and C) For both the day 10 (B) and day 45 (C)
time points, we calculated for each gene the
insertion count differences between the input
library and the recovered libraries from WT mice,
and a p value expressing the significance of these
differences. We then log transformed the p values
and gave each gene with a loss of insertions a
negative log-p value and each gene with a gain of
insertions a positive log-p value. After ordering the
genes based on their p values, we plotted each
gene as a dot with log-p values on the y axis and
the size of the circles representing the fold change
of insertion count differences.
See also Figure S1.counteractomes for physical stresses encountered in the host.
Using these, we focus on a particular bacterial pathway, trypto-
phan (Trp) synthesis, and find the host mechanism for inducing
amino acid starvation in intracellular mycobacteria. We go on
to find a small molecule that targets Trp synthesis, determine
the structural and biochemical basis of its activity, and show
that it acts together with the host to kill Mtb both in vitro and dur-
ing a model infection. Together, our findings demonstrate the
utility of profiling the pathogen response to host-mediated
stresses. We characterize the stresses induced by CD4 T cells
and leverage one stress, Trp starvation, to synergize with a small
molecule to more effectively treat TB.
RESULTS
Genes Required for Survival during Infection: Virulence
Factors
In order to define the set of Mtb genes required for surviving the
CD4 T cell response, we infected both wild-type (WT) and MHC
class II KO (MHCII/) mice with a library of Mtb transposon
mutants (Zhang et al., 2012). We injected 106 bacteria intrave-
nously and plated surviving bacteria from infected spleens at
10 days and 45 days after infection (Figure 1A). To identify
mutant Mtb in the surviving pools, we deep sequenced trans-
poson junctions to map the insertion site of each mutant. ForCell 155, 1296–1308, Deach time point, we made two compari-
sons. First, we compared the surviving
pool of mutants fromWTmice (WT output
library) to the inoculating pool (input
library), defining genes with a statistically
validated decrease in output library as
required for growth during infection,
commonly known as virulence factors(Figure 1A). Second, we compared the output library from WT
mice to the output library from MHCII/ mice (Figure 1A). In
effect, we screened for Mtb mutants with in vivo growth defects
that were rescued in the absence of CD4 T cells. We reasoned
that genes required for surviving the CD4 T cell response would
be required for growth in WTmice, but not required for growth in
MHCII/ mice, which lack CD4 T cells (Figure 1A). Because
these genes are responsible for counteracting the effects of
CD4 T cells, we refer to this set of genes as Mtb’s CD4
counteractome.
We found 576 genes that were required for growth during
infection (Figures 1B and 1C; see Figure S1A available online).
These genes had a statistically significant (false discovery rate
[FDR], q < 0.01) 10-fold or more decrease in insertion counts
across the gene. On day 10, 405 genes were required for growth
in vivo, and on day 45, 317 genes were required. A total of 146
genes were required at both time points (Figures 1B and 1C;
Table S1). Genes required late but not early could represent
mutants that are able to establish infection but unable to sustain
long-term in vivo growth. Genes required early but not late could
represent mutants that grow slowly in mice. These mutants
would be underrepresented at day 10 but catch up by day 45
postinfection. In fact, genes that were required at day 10 but
not at day 45 were enriched for loss of insertions (Figure S1B).
The average in vitro:in vivo ratio for these genes was 4.3,ecember 5, 2013 ª2013 Elsevier Inc. 1297
compared to the nonrequired average of 1.3 (p < 0.001) (Fig-
ure S1C). Although this set significantly overlapped with a
previously defined set of genes required for growth in mice
(gene set enrichment analysis [GSEA], p < 0.01), it also includes
more than 400 newly discovered genes required for in vivo
growth (Figure S2A) (Sassetti and Rubin, 2003).
GenesRequired for SurvivingCD4-Mediated Stress: The
CD4 Counteractome
To screen for the CD4 T cell counteractome, the set of mycobac-
terial genes required for counteracting CD4-mediated stress, we
searched for genes wherein mutations caused a growth defect in
WT mice, but not in CD4-deficient mice. By comparing the WT
output libraries to the MHCII/ output libraries, we found that
58 genes had a statistically validated increase in insertions in
MHCII/mice compared to WT mice. These genes had at least
a 5-fold increase in insertions and a Mann-Whitney U p value of
less than 0.05 (Figure 2A; Table S2). Two biochemical pathways,
gluconeogenesis and Trp biosynthesis, were enriched in this list,
suggesting that CD4 T cells are responsible for inducing a shift in
Mtb metabolic demands (Table S2).
The CD4 counteractome could be required for the bacterium’s
physiologic changes in response to CD4-driven environmental
changes. Thus, the counteractome is a signature that cues us
into the nature of CD4-mediated stress. To identify these cues,
we selected our Mtb transposon library in a series of in vitro
models of immune-driven stress conditions and compared the
counteractome signatures. Using the same transposon-map-
ping technique on our selected library, we tested carbon starva-
tion, amino acid starvation (and isolated Trp starvation), iron
depletion, acid stress, and nitrosative stress (Tables S3A, S3B,
S3C, and S3D). We created conditionally required gene sets as
well as ranked gene lists for each condition, which allowed us
to compare gene sets using the running-sum enrichment anal-
ysis in the GSEA tool (Subramanian et al., 2005). We found that
both nitrosative stress and acid stress had significantly similar
profiles to genes required for in vivo growth (Figure 2E, pairwise
comparisons of ‘‘Tyloxapol pH 4.5,’’ ‘‘pcit pH 4.5,’’ ‘‘DETA-NO,’’
and ‘‘in vivo day 45’’). This is consistent with the reactive nitrogen
species and low pH of Mtb’s in vivo niche (Ehrt and Schnap-
pinger, 2009; Vandal et al., 2008). Interestingly, we also found
that Trp starvation was enriched in the CD4 counteractome (Fig-
ure 2E, intersection of ‘‘tryptophan rescue’’ and ‘‘MHCII/
rescue day 9’’). Two genes in the Trp biosynthesis pathway,
trpD and trpE, had no insertions in the WT output library but mul-
tiple insertions in the MHCII/ output library (Figures 2B and
2C). To confirm this finding, we infected WT and MHCII/
mice with strains of Mtb auxotrophic for Trp. The growth of the
auxotrophs was significantly limited in WT mice but restored in
MHCII/ mice (Figure 2D). This suggested that CD4 T cells
induced the requirement for bacterial Trp biosynthesis and that
interfering with Trp metabolism might offer an appealing thera-
peutic strategy.
Trp Auxotrophy Is Bactericidal
To study the effects of Trp auxotrophy and starvation during Mtb
infection, we deleted the trpE gene in Mtb and replaced it with a
hygromycin-resistance gene (Figure 3A). TrpE, or anthranilate1298 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.synthase, converts chorismate to anthranilate in the first
committed step of Trp biosynthesis. The next enzyme in the
pathway, TrpD, converts anthranilate to N-(50-phosphoribosyl)-
anthranilate. An Mtb strain carrying a deletion of the trpD gene
has been shown to be a Trp auxotroph (Figure 3B) (Parish,
2003; Smith et al., 2001). The trpE deletion strain grew normally
in liquid media only when supplemented with 1 mM Trp (Fig-
ure 3C). Interestingly, lower amounts of Trp delayed entry into
the logarithmic phase of growth, but the growth dynamics from
that point onward was similar to WT. Genetic complementation
with the trpE gene restored normal growth in media lacking Trp
(Figure 3C).
Auxotrophy in Mtb is not always bactericidal (Parish, 2003).
Our results suggested that CD4 T cells help starve Mtb of exog-
enous Trp, so we sought to test the bactericidal potential of
blocking endogenous Trp biosynthesis in the face of this exoge-
nous starvation. To do so, we cultured the auxotroph in Trp to
both midlog and stationary phase, continued the culture either
in the presence or absence of Trp, and measured bacterial
survival. The auxotroph was rapidly killed when starved of Trp,
suggesting that Trp biosynthesis is an attractive target for a
bactericidal drug (Figures 3D and 3E). Interestingly, the trpE
deletion strains die far more rapidly than a trpD deletion (Parish,
2003). The trpE deletion strain has about a 100,000-fold loss of
viability at 2 weeks, a level that is reportedly not achieved after
13 weeks of starvation of the trpD deletion strain. This may be
due to accumulation of intermediary metabolites or the presence
of an as yet undescribed alternative Trp synthesis pathway.
Trp Auxotrophs Are Hypersusceptible to Macrophages
Activated by CD4 T Cells
During a typical lung infection, Mtb first enters alveolar macro-
phages, which then form an inflammatory structure known as
the granuloma. Upon adaptive immune activation, CD4 T cells
enter the granuloma and stimulate the infected macrophages
(Ernst, 2012). Our screen results suggested that one of these
stimulatory mechanisms imposes a need for bacterial Trp
biosynthesis, and we sought to delineate the mechanism by
which CD4 T cells exert this need. To do so, we infected thiogly-
colate-elicited mouse peritoneal macrophages with WTMtb, the
trpE deletion strain and the complemented strain. Over a 5-day
infection, the WT and complemented strains increased in col-
ony-forming units (cfu) by about 5-fold, whereas the trpE deletion
strain had no measurable growth, demonstrating that Trp
biosynthesis is required for growth even in unstimulated macro-
phages (Figure 4A).
Our mouse findings predicted that the trpE deletion strain
would be particularly sensitive to CD4-mediated stress. Indeed,
the trpE deletion strain was significantly hypersusceptible to the
effects of CD4 T cells in coculture with macrophages (Figures 4A
and 4B). By adding CD4 T cells harvested from the spleens of
Mtb-infected mice, macrophages were able to kill the auxotroph
more effectively. Compared to unstimulated macrophages, CD4
T cell-stimulated macrophages decreased growth of WT Mtb by
about 50%, whereas CD4 coculture decreased trpE deletion
strain growth by about 80% (Figure 4B). Additionally, the trpE
deletion strain was also hypersusceptible to IFN-g and TNF-a,
cytokines secreted upon the arrival of CD4 T cells to an Mtb
Figure 2. Trp Biosynthesis Is Required during Infection of WT, but Not MHCII/, Mice
(A) To search for genes required for surviving the CD4 T cell response, we identified genes that had a statistically validated increase in insertion counts (above
the axis).
(B and C) Transposon insertion counts in the regions containing trpE (B) and trpD (C) are illustrated. Histograms represent the number of times insertions were
found at each potential insertion site. Both trpE and trpD sustained insertions in our library, but whereas we were unable to retrieve insertions in these genes from
WT mice, we were able to recover trpE and trpD mutants from MHC class II KO mice.
(D)We infectedWT, trpEKO, and complemented strainMtb intoWT andMHCclass II KOmice. Growth of the three strains was determined, confirming the results
of our transposon screen. Error bars represent SE.
(E) By comparing gene-requirement signatures, we profiled the similarity of CD4-mediated stress to in vitro models of potential immune-mediated stresses. Each
box represents a pairwise comparison between two gene sets, where the larger gene set was ordered by p value and ratio, and the smaller gene set was used by
the GSEA preranked tool to search for the enrichment of the second set of genes in the first.
See also Figure S2.lesion (Figures S3A and S3B). These data confirmed our findings
in mice and showed that CD4 T cells and the cytokines they
secrete demand the need for mycobacterial Trp biosynthesisduring infection. Because human macrophages differ from
mouse macrophages in their mycobacterial-killing strategies,
we tested the growth of our Mtb strains in monocyte-derivedCell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc. 1299
Figure 3. Mtb Trp Auxotrophs Are Cleared during Infection and Die
In Vitro during Starvation
(A) We constructed a Trp auxotroph in Mtb by replacing trpE with a
hygromycin-resistance cassette.
(B) Trp biosynthesis starts with the conversion of chorismate to anthranilate by
TrpE, followed by ribosylation by TrpD.
(C) Trp auxotrophs, complemented strains, and WT Mtb were grown in the
presence and absence of Trp in 7H9 media. No Trp was required for WT and
complement growth, but 1 mM Trp was required to restore normal growth of
the Trp auxotroph.
(D and E) Auxotrophs grown to midlog (D) and stationary (E) phase were
washed, starved of Trp, and plated for cfu. Starvation of the auxotroph resulted
in rapid mycobacterial death.
All error bars denote SEM.macrophages from human donors. As with previous reports, we
observed that IFN-g alone does not measurably inhibit WT Mtb
growth (Fabri et al., 2011). However, whereas the trpE deletion1300 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.strain grew slightly over the 5-day infection, its growth was
inhibited by IFN-g (Figure 4E).
IFN-g Induction of IDO Necessitates Mycobacterial Trp
Biosynthesis
To show that the auxotroph’s hypersusceptibility to IFN-g was
Trp dependent, we added Trp to the media in IFN-g-treated
macrophages, which reversed the IFN-g hypersusceptibility
(Figure S3E). As expected, Trp did not change the bacterial
growth inhibitory effect of IFN-g in WT Mtb, showing that Trp
supplementation does not have a general growth effect on Mtb
(Figure 4E). Interestingly, Trp supplementation could not restore
growth of the auxotroph in unstimulated macrophages to WT
Mtb levels. It is possible that the levels of Trp needed to restore
WT growth (1 mM in liquid broth) cannot be reached intracellu-
larly, whereas the amount of Trp required to protect from IFN-
g-mediated killing could.
Many intracellular pathogens are natural Trp auxotrophs
whose intracellular growth is also inhibited by IFN-g. Thus, we
attempted to determine if similar processes affected Trp avail-
ability in Mtb infection. One of the transcriptionally induced
genes in response to IFN-g is a Trp-catabolizing enzyme: indole-
amine-2,3-dioxygenase (IDO) (Alberati-Giani et al., 1997). IDO
utilizes Trp as a synthetic precursor for kynurenines, immune
signaling molecules that help control inflammation (Zelante
et al., 2009). In this synthetic process, it also greatly decreases
the intracellular Trp pool. IDO is thus required for IFN-g-medi-
ated growth inhibition of Chlamydia and other Trp auxotrophic
intracellular pathogens (Ibana et al., 2011; Zelante et al., 2009).
We tested the role of IDO in the trpE deletion strain’s hypersus-
ceptibility to CD4 T cell and IFN-g by either (1) inhibiting IDO in
both human and mouse macrophages with a specific chemical
inhibitor, 1-methyl Trp (1-MT) (Figures 4C and 4E), or (2) using
mouse macrophages derived from IDO KO mice (Figure 4D). In
both cases, the hypersusceptibility was reversed. The inhibitor
acts on the macrophage rather than the pathogen because it
had no effect on bacteria grown in a defined medium (Fig-
ure S3D). These data support that CD4 T cells, likely acting
through IFN-g, stimulate intracellular Trp depletion, forcing Mtb
to synthesize its own Trp.
Halogenated Anthranilate Analogs Disrupt Trp
Biosynthesis to Kill Mtb In Vitro
Because Trp is required for intracellular growth in the face of
CD4-mediated immunity, compounds that inhibit the bacterial
Trp synthesis pathway should synergize with host immunity.
We focused on anthranilate analogs, compounds that have
been shown to inhibit the synthesis of quorum-sensing mole-
cules in Pseudomonas aeruginosa that, like Trp synthesis, also
have an anthranilate intermediate (Lesic et al., 2007). We tested
a panel of anthranilate analogs for Mtb growth inhibition in the
presence and absence of Trp. Two fluorinated anthranilates,
2-amino-5-fluorobenzoic acid (5-FABA) and 2-amino-6-fluoro-
benzoic acid (6-FABA), had an MIC of 5 mM in liquid broth in
the absence of Trp (Figure 5A). The addition of Trp blocked
toxicity (Figure 5A). 6-FABA was less active againstMycobacte-
rium smegmatis (Msm), with an MIC of 65 mM, but this was,
again, blocked by added Trp (Figure S4). As predicted from the
Figure 4. Trp Starvation of Trp Auxotrophs
by Macrophages Requires IDO
(A) WT, Trp auxotroph, and complemented strains
were used to infect macrophages. One day
after infection, macrophages were either stimu-
lated with CD4 T cells in coculture or remained
unstimulated.
(B) The Trp auxotroph grew poorly in unstimulated
macrophages and was hypersusceptible to the
effects of CD4 T cells.
(C) Macrophages were stimulated by either
immune CD4 T cells (CD4 T cells isolated from
spleens of Mtb-infectedmice) or IFN-g and TNF-a.
(D) To test whether the hypersusceptibility of the
auxotroph was dependent on IDO, we also
inhibited IDO with its small-molecule inhibitor,
1-MT, or used macrophages isolated from IDO
KO mice.
(E) Human monocyte-derived macrophages were
infected withWT and Trp auxotroph bacteria. After
stimulation with IFN-g, we showed that the Trp
auxotroph was also hypersusceptible to the
effects of human IFN-g.
See also Figure S3.experiments with auxotrophs, 6-FABA was also bactericidal in
liquid broth (Figure 5B) with an 100-fold and 10,000-fold
decrease in cfu compared to the starting inoculum or the
untreated control on day 6, respectively.
To determine the likely target of these compounds, we
selected for mutants on solid media containing 150 mM
5-FABA or 300 mM 6-FABA. We plated 109 bacteria treated
with 0.25% ethyl methanesulfonate on 150 mM 5-FABA, which
resulted in 30 resistant colonies. We then sequenced the
genome of a resistant clone and found the following poly-
morphisms: TrpE:F68I, Rv2585c:A154V, Pks13:P568A, and
4359303:A > G (downstream of RD1 deletion). The trpEmutationCell 155, 1296–1308, Dwas surprising because the enzyme
converts chorismate into anthranilate,
and we had hypothesized that TrpD,
which utilizes anthranilate, would be the
target of these anthranilate analogs. This
led to two competing hypotheses for the
mechanism of resistance. The FABA
molecules could target TrpE by inhibiting
the enzyme at its allosteric site, and the
F68I mutation might confer resistance
to this targeting. Alternatively, the F68I
mutant could be a hypermorph, and
insensitivity to allosteric inhibition by
Trp might confer resistance through
increased Trp synthesis.
Testing the possibility that the FABAs
are inhibitors of TrpE activity was techni-
cally challenging. We cloned and purified
bothWT and the F68I mutant form of TrpE
and assayed their activity by measuring
the fluorescent product, anthranilate
(Baker and Crawford, 1966). Both anthra-
nilate-derivative FABA compounds hadfluorescent spectra that overlapped with anthranilate. Therefore,
we were unable to assess the possibility of the FABA com-
pounds being inhibitors of TrpE. However, we were able to test
the enzymatic properties of both mutant and WT TrpE and
address the possibility of a hypermorphic allele. Indeed, we
found that themutant enzyme had a 3-fold increase in in vitro ac-
tivity compared to the WT enzyme (Figure 5C). Furthermore, the
mutant enzyme was 50 times less sensitive to allosteric inhibi-
tion by Trp in vitro (Figure 5D). When we modeled the Mtb TrpE
structure using the Serratia marcescens homolog, we found that
F68 resides in the allosteric binding pocket of Trp (Figure 5E).
Altogether, this suggests that the F68I mutant is a hypermorphicecember 5, 2013 ª2013 Elsevier Inc. 1301
Figure 5. A Small Molecule, 6-FABA, Tar-
gets Mycobacterial Trp Biosynthesis
(A) 6-FABA inhibits the growth of Mtb in 7H9. For 6-
FABA inhibition of M. smegmatis growth, please
see Figure S4.
(B) To test the bactericidal potential of 6-FABA,WT
Mtb was treated with 6-FABA in 7H9, and cultures
were plated for cfu at various time points.
(C) WT (black) and mutant TrpE (F68I; blue) were
isolated, and enzymatic activity was assessed by
measuring chorismate concentration.
(D) The inhibitory effect of Trp on both WT (blue)
and mutant (black) TrpE was measured as percent
(%) initial velocity of the no-inhibitor control reac-
tion.
(E) Mtb TrpE structure (blue) was modeled based
on the homologous enzyme from S. marcescens
(beige), showing F68 in the allosteric binding
pocket of Trp.
See also Figure S5.allele that is also less sensitive to allosteric inhibition by Trp. The
likely increase in Trp production, then, confers resistance to the
FABA compounds in the same way that added exogenous Trp
does (Figures 3C–3E).
6-FABA Synergizes with IFN-g to Kill Mtb in
Macrophages
If these compounds act through the Trp biosynthetic pathway,
they should phenocopy trpE deletion strains during macrophage
infection. To test this, we infected macrophages with Mtb and,
after 1 day, added 6-FABA and measured bacterial growth by
plating for cfu on day 5. At concentrations as low as 10 mM, 6-
FABA significantly limited growth by over 10-fold (Figure 6A).
The number of cfu at day 5 was lower than at day 1, demon-
strating that 6-FABA had bactericidal activity in macrophages.
To ensure that activity was not due to the death of macrophages,
we tested cytotoxicity and found that 6-FABA did not affect cell
viability (Figure S5A).
Because the Trp auxotroph was hypersusceptible to IFN-g,
we hypothesized that 6-FABA’s block of Trp biosynthesis would
work in synergy with IFN-g to kill Mtb in macrophages. To test
this, we dosed both IFN-g (10 U/ml) and 6-FABA (0.2 mM) to a1302 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.level where each individually had about
a 2-fold inhibitory effect on bacterial
growth (Figure 6B). Without synergy, we
predicted that the combined effect of 6-
FABA and IFN-g would be about 4-fold.
Instead, the effect was40-fold in mouse
and 9-fold in human macrophages,
demonstrating clear synergy (Figures
6C, S5B, and S5C).
6-FABA Inhibits Mtb Growth during
Infection
Although many compounds are active
in vitro, few have adequate bioavailability
to be used in animal infections without
considerable modification. Fortunately,however, we found that both 6-FABA and an ester derivative
(that is rapidly cleaved to the free acid in the circulation) are ab-
sorbed orally and achieve high serum concentrations, though
with relatively short half-lives (Figure S6). Moreover, doses of
up to 250 mg/kg/day did not result in clinical illness or weight
loss during a 5-day tolerability trial. This allowed us to test the ac-
tivity of these compounds in a mouse model of TB.
We infected mice with 102 aerosolized Mtb bacilli and allowed
infection to establish in the lungs for 8 days. We treated mice six
times a week with INH (25mg/kg/day), 6-FABA (200mg/kg/day),
or the ester derivative (200 mg/kg/day) and planned to measure
bacterial growth at 2 and 4 weeks after initiating treatment. Un-
fortunately, prolonged treatment with 6-FABA resulted in 50%
death of animals within 4 weeks. Thus, we could only evaluate
2-week efficacy with this compound. Notably, the ester form of
6-FABA was not toxic, even though it releases the same amount
of 6-FABA in mouse serum. This suggested to us that toxicity of
6-FABA was due to an as of yet undetermined off-target effect
that might be influenced by an interaction with anesthesia used
for gavaging Mtb-infected animals (anesthesia was not used
for tolerability trial). Importantly, the nontoxic ester derivative al-
lowed us to assess the in vivo efficacy of pharmaceutical Trp
Figure 6. 6-FABA Synergistically Inhibits
Mtb Growth in Macrophages and Mice
(A) WT Mtb was used to infect macrophages. On
day 1 after infection, macrophages were treated
with 6-FABA, and on day 5, cells were lysed and
bacteria plated, showing that the 6-FABA was
bactericidal in macrophages.
(B) To test the synergy between 6-FABA and IFN-g,
we added 6-FABA and IFN-g at concentrations
that inhibited approximately half of bacterial
growth.
(C) Together, their effect was greater than the
estimated additive effect of the two molecules in
the absence of synergy, showing that they indeed
work synergistically to kill Mtb in macrophages.
Mice were infected with 102 aerosolized Mtb
bacilli. After 8 days of infection, mice were treated
with INH (25 mg/kg), 6-FABA (200 mg/kg), or with
the ester derivative of 6-FABA (200 mg/kg).
(D–G) At 2 weeks (D and E) and 4 weeks (F and G)
after infection, lungs and spleens were homoge-
nized and plated for cfu.
*p < 0.05 and **p < 0.01. Insets show linear scale
cfu. Error bars denote SEM.
See also Figure S6.biosynthesis targeting over a longer time period. At 2 weeks after
infection, growth in mouse spleens was decreased by greater
than 10-fold in both 6-FABA and the ester derivative-treated
mice (Figure 6E). 6-FABA also decreased bacterial growth in
the lungs, but to a lesser extent (Figure 6D). At 4 weeks after
infection, the ester continued to significantly decreasemycobac-Cell 155, 1296–1308, Dterial growth in both spleens and lungs
(Figures 6F and 6G). The effect of these
molecules on decreasing bacterial growth
in vivo demonstrates that Trp biosyn-
thesis is a viable target for drug develop-
ment. Combined with the fact that CD4
T cells are required for optimal killing of
Trp auxotrophs (Figure 2D), we have
shown that this therapeutic strategy lever-
ages CD4 T cell activity to kill Mtb in vivo.
DISCUSSION
CD4 T cells are paramount in the host
defense against TB but are insufficient to
clear the bacteria from a diseased patient.
We found that one of the mechanisms by
which bacteria survive host CD4-
generated stress is through the produc-
tion of Trp, thus avoiding starvation and
death. Loss or inhibition of the Trp
biosynthetic pathway renders Mtb hyper-
susceptible to IFN-g-mediated killing
within macrophages, both in vitro and
during infection (Figure 7).
This observation highlights one of the
major mechanisms of host protectionagainst invading organisms: depriving them of key nutrients.
Infection triggers host responses that sequester important com-
pounds such as amino acids and iron (Hood and Skaar, 2012;
Zhang and Rubin, 2013). Although these nonspecific responses
are likely important for the control of poorly adapted invaders,
successful pathogens have developed strategies to counteractecember 5, 2013 ª2013 Elsevier Inc. 1303
Figure 7. A Model for Trp Starvation as an
Antimycobacterial Mechanism
(A) Upon infection, unstimulated macrophages
contain high levels of Trp, which together with Trp
synthesized by the bacterium is able to support
Mtb growth.
(B) CD4 T cells, through IFN-g and the induction of
IDO, decrease the amount of intracellular Trp
available to Mtb, demanding the need for myco-
bacterial Trp biosynthesis for bacterial survival.
(C) Treatment with 6-FABA chemically induces
Mtb Trp auxotrophy. Together with immune-
mediated Trp starvation, this results in mycobac-
terial death.these defenses, including biosynthesis of key compounds and
efficient scavenging of others. Mtb in particular relies upon
cholesterol and fatty acid catabolism, gluconeogenesis, and
the glyoxylate shunt to survive the host environment (Lee et al.,
2013; Marrero et al., 2010; McKinney et al., 2000; Mun˜oz-Elı´as
and McKinney, 2005; Pandey and Sassetti, 2008).
Trp starvation, through IDO-mediated depletion of cyto-
plasmic pools of this amino acid, appears to be a mechanism
that has the added benefit of leading to kynurenine production
and prevention of immunopathology (Desvignes and Ernst,
2009). This clearly benefits the host in blocking the growth of
cytoplasmic pathogens. However, it is less obvious that it should
be a successful strategy for vacuolar organisms that do not have
ready access to the cytoplasm. In the case ofmycobacteria, sus-
ceptibility of Trp auxotrophs to IDO-mediated killing means that
bacteria must be able to access this amino acid. This could
occur through specific host or bacterial transport mechanisms
(that have not been defined) or direct access to the cytoplasm
through either partial or complete loss of vacuolar integrity, a
model consistent with recent observations of Mtb escape into
the cytoplasm (Hagedorn et al., 2009; McDonough et al., 1993;
van der Wel et al., 2007). The apparent ability of Mtb to scavenge1304 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.for Trp points toward a capability to
uptake other amino acids. A host of other
Mtb amino acid auxotrophs are attenu-
ated for growth in mice; it is possible
that this is due to immune-driven starva-
tion mechanisms (Hondalus et al., 2000;
Pavelka et al., 2003; Price et al., 2011;
Tattoli et al., 2012; Zhang and Rubin,
2013).
Although scavenging Trp in MHCII/
mice allows the Trp deletion strains to
survive, it is important to note that these
mutants are eventually attenuated even
in MHCII/ mice. Similarly, we showed
that the TrpE deletion strain is attenuated
in macrophages even before stimulation
by CD4 T cells or IFN-g and TNF-a.
So, whereas our data clearly demon-
strate the importance of CD4 T cells in
demanding bacterial Trp synthesis, it
appears that there may also be CD4-independent mechanisms of Trp starvation. Importantly, this
suggests that targeting Trp biosynthesis would retain some
effectiveness even in patients, such as HIV-positive individuals,
who lack a normal CD4 compartment.
Here, we used an improved analytic approach to identify
conditionally essential genes using a transposon library. Each
gene has multiple potential insertion sites, and most insertion
count comparisons sum counts across each gene to compare
between conditions. However, in reasonably saturated libraries,
treating each potential insertion site as an independent assess-
ment of gene requirement drastically increased the statistical
power of such comparisons. Most transposon insertion-
sequencing techniques currently use insertion count totals
summed across all sites in a gene (Goodman et al., 2009; Griffin
et al., 2011). We found that this drastically decreases the power
of statistical hypothesis testing and increases the likelihood that
a single differential site could make the entire gene look differen-
tially required. We developed a more discriminating method for
assessing the conditional requirement of genes in genome-
wide bacterial transposon screens. Using an easily scalable
nonparametric test to comprehensively compare the distribution
of insertion counts (rather than the sums of insertion counts)
across every gene, we were able to assess genetic requirement
across a host of different conditions.
In contrast to similar microarray-based screens, deep
sequencing allowed us to directly map insertion sites for each
surviving mutant and, thus, improved significantly on the sensi-
tivity and specificity of insertion count comparisons. We found
576 genes that were required for growth in vivo, most of which
are newly described as required. Furthermore, by searching for
mutants rescued for growth in MHCII/ mice, we described
58 genes that were likely required for surviving CD4-mediated
host defenses.
One power of this approach is that we can easily compare
gene requirements in multiple conditions, essentially using com-
plex profiles to identify critical environmental determinants. We
showed that the in vivo environment as a whole, as well as the
specific CD4-generated component of that environment, could
be understood by comparing multiple gene-requirement pro-
files. GSEA comparing in vivo profiles to in vitro profiles
confirmed that Mtb’s infectious niche is characterized by acidic
and oxidative stress and that CD4 T cells impose Trp starvation.
Gene-requirement signatures are an effective way to understand
both mycobacterial physiology as well as the environments
created by components of host immunity. Our study is limited
to the determination of the CD4 counteractome, but other
counteractomes—those specific to IFN-g, iNOS, CD8 T cells,
or any immune system component that can be perturbed in a
mouse—will further our understanding of the tug-of-war
between host and pathogen. In fact, given that many CD4-
mediated mechanisms are IFN-g dependent, we would predict
that bacterial strains rescued in the MHCII/ mice, like the
trpE deletion strain, would also be rescued in IFN-g KO mice.
Thus, on a genomics scale, the IFN-g counteractome should
look similar to the CD4 counteractome. Further profiling can
test such hypotheses and uncover new mechanistic differences
between the many arms of host immunity.
Trp biosynthesis is an attractive target for antibiotic develop-
ment. Small-molecule inhibitors of Trp and other aromatic amino
acid biosynthesis exist for other organisms, suggesting that
certain enzymes in these pathways might be ‘‘druggable,’’ or
suitable for chemical inhibition (Coggins et al., 2003). Further-
more, Trp is an essential amino acid for humans (WHO, 2007)
Because hosts get all of their needed Trp from their diets, any
cross-species activity of anti-Trp synthesis drugs should be
nontoxic (though off-target toxicity remains a possibility).
Halogenated anthranilates were first described as inhibitors of
both quorum sensing and growth in P. aeruginosa infection
(Lesic et al., 2007). We found that two of these compounds,
6-FABA and 5-FABA, had bactericidal activity against Mtb at
low concentrations, though only in the absence of Trp. Two lines
of evidence suggest that Trp biosynthesis pathway is the phys-
iologic target for both of these compounds. First, normal bacte-
rial growth is restored during FABA treatment by the addition of
Trp. Second, resistant mutants harbor a hypermorphic enzyme
that is resistant to allosteric inhibition by Trp. Together, these
provide chemical and genetic confirmation that Trp can rescue
the effect of FABA, but it does not prove that FABA inhibits Trp
production. Because TrpD utilizes anthranilate as a substrate,
we speculated that 6-FABA might be a competitive inhibitor ofTrpD. However, it is also possible that 6-FABA could be a
substrate of TrpD, resulting in the production of fluorinated inter-
mediates that inhibit Trp biosynthesis or even fluorinated Trp that
incorporates into and poisons protein synthesis or function. Our
data clearly demonstrate that the bactericidal activity of 6-FABA
is due to its negative effect on Trp biosynthesis, and further
studies to elucidate the precise mechanism of toxicity should
focus on this Trp effect.
The vast majority of antibiotics are effective against organisms
grown in vitro. However, one of the most effective antitubercu-
losis drugs, pyrazinamide, is poorly active under most in vitro
growth conditions (Tarshis and Weed, 1953; Zhang and Mitchi-
son, 2003). Instead, it relies on the host environment for efficacy.
Similar compounds, which target processes critical in the host,
could effectively synergize with the host response to infection
and have substantial efficacy. Probing CD4-mediated immunity
helped us identify a specific facet of the host-derived environ-
ment that could be utilized for bacterial killing. Although we do
not yet have a compound that is highly effective during infection,
our results provide genetic and chemical validation of the Trp
biosynthesis pathway as a target for highly active antibiotics.EXPERIMENTAL PROCEDURES
Library Generation
Transposon libraries were created as described previously (Zhang et al., 2012)
but plated on 7H10 plates with glycerol, OADC, Tween 80, Cas-amino acids,
and Trp. A total of 500,000 mutants were scraped, frozen, and saved for
future use.
Mouse Infections and Harvests
WTmice (C57BL/6) were obtained from Jackson Laboratory. MHC class II KO
mice (Abb H2-Ab1) were obtained from Taconic Farms. Mice were infected
with 106 bacteria via tail vein injection. At 10 and 45 days postinfection, spleens
were harvested and plated for bacteria. For each mouse, 106 surviving
colonies were scraped, and DNA was extracted for analysis. The protocols,
personnel, and animal use were approved and monitored by the Institutional
Animal Care and Use Committee. The animal facilities are AAALAC accredited.
In Vitro Transposon Library Selections
For acid stress, the library was suspended in liquid media at a starting concen-
tration of 108 cfu/ml and selected in 7H10 with tyloxapol (in place of Tween 80)
buffered to pH 6.5 or pH 4.5, and in phosphate-citrate buffer at pH 4.5.
Bacteria were plated after 6 days and scraped for DNA prep. For nitrosative
stress, the library was suspended in 5 mMDETA-NO for 3 days. Trp starvation
and amino acid starvation were measured using libraries that were created
either on normal 7H10, or on 7H10 supplemented with 1 mM Trp or 1%
Cas-amino acids, respectively. Iron-supplemented libraries were plated on
7H10 with 450 mM and 1.5 mM iron. All primary data can be found in Tables
S1, S2, S3, and S4. All the raw data are available in Table S4.
Statistical Analysis
For each insertion count comparison, the control libraries were combined
using a script that normalized insertion counts to the sequencing run’s total
read counts. This combined control library was then used to compare to
each experimental library. For each gene, we treated the insertion counts at
sites within the middle 90% of the gene as nonparametric distributions and
assumed the null hypothesis that the distributions would be the same between
conditions. We used a Mann-Whitney U test for hypothesis testing. A p value
was thus calculated for each replicate, and a composite p valuewas generated
by using a Bonferroni correction and Fisher’s method. We then generated
Benjamini-Hochberg FDRs using the composite p values. Ratios wereCell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc. 1305
calculated by averaging the read counts per gene for all replicates and
comparing to the combined control library, after normalizing for total read
counts.
GSEA
GSEA was performed using the preranked tool. Genes were stratified by
p value (<0.01 or 0.05 and > 0.01 or 0.05) and then ranked by ratio within the
strata. For each conditional gene-requirement experiment, a ranked list and
a conditional essential ‘‘calls’’ gene set were created. Each ranked list was
then assessed against each gene set, and familywise error rate was used to
generate the p values for significant enrichment.
Construction of trpE Deletion and Complement Strains
The hygromycin-resistance gene was amplified with flanks containing 500 bp
regions upstream and downstream (and slightly overlapping with) of trpE. This
construct was electroporated into a recombineering strain of Mtb containing
the plasmid pNIT(kan)::RecET-SacB. Transformations were plated on 7H10
agar with 1 mM Trp. Positive clones were plated on 7H10 agar containing
10% sucrose to counterselect against the recombinase plasmid. Deletion of
the endogenous locus was confirmed by PCR and by phenotypic tests for
auxotrophy. Finally, to complement, the trpE-rv1610 two-gene operon was
amplified and cloned, along with an artificial promoter, using multisite gateway
into pDE43-MCK, which integrates into the L5 site.
Macrophage Infections
Peritoneal macrophages were stimulated with thioglycollate medium (3%) by
intraperitoneal infection, harvested 3–5 days poststimulation, and isolated
using CD11b MicroBeads (Miltenyi Biotec). Human monocyte-derived macro-
phages were made from donated buffy coats. Ficoll-separated cells were
harvested, and macrophages were isolated with CD14 MicroBeads (Miltenyi
Biotec) and grown in GM-CSF (10 ng/ml) for 5 days before use. Cells were
infected withMtb at anmoi of 10:1 for 2 hr at 37C and then washed four times.
On day 1 postinfection, most conditions were added. To lyse cells, Triton
X-100 (0.1%) in PBS was added to each well. Serial dilutions of the lysis
were made and plated. For CD4 T cell coculture, we infected mice with 100
aerosolized cfu of Mtb. Spleens from infected mice were harvested no earlier
than 6 weeks postinfection, and CD4 T cells weremagnetically isolated using a
T Cell-Negative Selection Kit (Miltenyi Biotec) and concurrent negative selec-
tion of CD8 T cells.
Kinetic Analysis of WT and Mutant Anthranilate Synthase
Amaster mix containing 100mMNH4Cl, 10mMMgCl2, 0.1 mMEDTA, 1 mMof
WT or mutant TrpE, 20 mM chorismate, and 20 mM of Tris (pH 9) was made for
each reaction to a final volume of 199 ml. Either Trp or 5-flurotryptophan was
also added in 1 ml amounts at concentrations ranging from 0.025 to 24 mM.
The readings for fluorescence emission (anthranilate) within the range of
480–512 nM were taken using the POLARstar Omega plate reader.
Alamar Blue Assays
In a 96-well plate, bacterial cultures were started at an OD600 of 0.003. After
5 days, resazurin reagent was added, and cells were kept in a shaking 37C
incubator for another 1–2 days. Plates were read, and theMIC was determined
as the first concentration at which the color changes.
Mouse Pharmacokinetic Study and Sample Preparation
A single dose of 5-FABA, 6-FABA, and the corresponding esters was admin-
istered intraperitoneally or orally at 25 mg/kg to female CD-1 mice, 4–6 weeks
of age. Blood samples were collected in heparinized tubes at six to eight serial
time points between 0 and 24 hr postdosing. Plasma was recovered following
centrifugation for 10 min at 1,000 3 g. Plasma levels of 5-FABA, 6-FABA, and
the corresponding esters were quantified by high-pressure liquid chromatog-
raphy coupled to tandem mass spectrometry (LC-MS/MS) following protein
precipitation with a 9:1 acetonitrile-to-plasma ratio, with diclofenac as internal
standard. Standards, quality control samples, and blanks in commercial
mouse plasma were used.1306 Cell 155, 1296–1308, December 5, 2013 ª2013 Elsevier Inc.LC-MS Conditions
The analysis was performed on a Sciex Applied Biosystems API4000
triple-quadrupole mass spectrometer coupled to an Agilent 1260 HPLC sys-
tem. Sample analysis was accepted if the low-level quality control samples
were within ±20% of nominal concentration and ±15% for mid- and high-level
quality control samples.
Acetonitrile with 0.1% formic acid was used as extractant. Gradient elution
conditions with a Fluophase 2.13 100 mm 5 U column were used. The mobile
phase A was 0.1% formic acid in deionized water, and mobile phase B was
0.1% formic acid in acetonitrile. The flow rate was 0.6 ml/min.SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cell.2013.10.045.
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